Analysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Target Price at $4.86

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has been assigned a consensus rating of “Moderate Buy” from the nine analysts that are covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $4.8571.

RVPH has been the topic of several recent research reports. Maxim Group cut their target price on Reviva Pharmaceuticals from $5.00 to $2.00 and set a “buy” rating on the stock in a report on Friday, August 15th. Chardan Capital started coverage on Reviva Pharmaceuticals in a research note on Monday, September 29th. They issued a “buy” rating and a $2.00 price objective on the stock. Wall Street Zen upgraded Reviva Pharmaceuticals to a “sell” rating in a research note on Saturday, October 4th. Benchmark dropped their price objective on Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating on the stock in a research note on Monday, September 15th. Finally, D. Boral Capital dropped their price objective on Reviva Pharmaceuticals from $3.00 to $2.00 and set a “buy” rating on the stock in a research note on Friday, September 19th.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Institutional investors have recently made changes to their positions in the business. 683 Capital Management LLC bought a new position in Reviva Pharmaceuticals during the second quarter valued at about $381,000. Armistice Capital LLC bought a new position in Reviva Pharmaceuticals during the second quarter valued at about $1,026,000. XTX Topco Ltd bought a new position in Reviva Pharmaceuticals during the second quarter valued at about $31,000. Persistent Asset Partners Ltd increased its stake in Reviva Pharmaceuticals by 300.0% during the second quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock valued at $244,000 after acquiring an additional 480,864 shares during the period. Finally, Geode Capital Management LLC increased its stake in Reviva Pharmaceuticals by 6.9% during the second quarter. Geode Capital Management LLC now owns 448,202 shares of the company’s stock valued at $171,000 after acquiring an additional 29,063 shares during the period. 63.18% of the stock is currently owned by institutional investors.

Reviva Pharmaceuticals Price Performance

NASDAQ RVPH opened at $0.57 on Monday. Reviva Pharmaceuticals has a fifty-two week low of $0.25 and a fifty-two week high of $4.28. The stock’s 50-day moving average is $0.48 and its two-hundred day moving average is $0.60. The firm has a market cap of $39.84 million, a P/E ratio of -0.88 and a beta of -0.08.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.03. On average, equities analysts expect that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.